Liraglutide add-on to metformin improves postprandial glucose control compared with metformin monotherapy in patients with Type 2 diabetes: posthoc analysis of the Liraglutide Effect and Action in Diabetes (LEAD)2 study

Similar Items

• Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
  by: Hermansen, K, et al.
  Published: (2010)
• Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
  by: Nauck, M, et al.
  Published: (2009)
• Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes
  by: Nauck, M, et al.
  Published: (2009)
• Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
  by: Jendle, J, et al.
  Published: (2009)
• Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data
  by: Frid, A, et al.
  Published: (2009)